# Norcliffe Capital

> Norcliffe Capital is a VC fund in Wadhurst backing Medical, Biotechnology and Biopharma. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Wadhurst, United Kingdom
- Total investments: 9
- Last investment: Jun 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/norcliffe-capital-limited/
- X (Twitter): https://twitter.com/norcliffecapit1
- Website: https://www.norcliffe.capital/

Norcliffe Capital is a VC fund in Wadhurst focused on Medical and Biotechnology. Norcliffe Capital provides tax-efficient investments in the life science and disruptive technology sectors.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 56% |
| Biotechnology | 4 | 44% |
| Biopharma | 2 | 22% |
| Health Care | 2 | 22% |
| Life Science | 2 | 22% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 56% |
| Series A | 2 | 22% |
| Funding Round | 1 | 11% |
| Venture - Series Unknown | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 6 | 67% |
| United States | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Laverock Therapeutics | Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies. The company builds a platform that uses endogenous microRNA and gene regulatory mechanisms to enable precise, tunable control of gene expression, allowing engineered cells to activate or silence therapeuticfunctions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases. |  | Seed | Jun 30, 2025 |  |
| Dxcover | Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $6.2M |  | Feb 03, 2025 |  |
| Oxford Endovascular | Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal. | $10.2M | Series A | May 20, 2024 |  |
| Glen Clova Scientific | Glen Clova Scientific is a company that developing a new gneration of active biological drugs. | $5M | Seed | Apr 24, 2024 |  |
| SMi Systems | SMi Systems is a biomedical research and medical equipment manufacturing organization. | $7.6M | Seed | Jun 14, 2023 |  |
| Dxcover | Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $9.3M | Series A | Feb 01, 2023 |  |
| Aureum Diagnostics | Aureum Diagnostics is a point of care diagnostics platform and medical equipment manufacturing organization. |  | Seed | Jan 01, 2023 |  |
| Biosceptre | Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Our focus is a multiple-targeted universal CAR T system with the potential to improve the lives of millions of patients across the world who are suffering from a wide range of malignancies. | $9.6M | Venture - Series Unknown | Mar 09, 2021 |  |
| Dxcover | Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $1.5M | Seed | Mar 04, 2021 |  |

9 of 9 investments shown.

## Co-investors
- [Eos](https://shizune.co/investors/profile/eos-advisory) — VC Fund, 5 deals together
- [University of Strathclyde](https://shizune.co/investors/profile/university-of-strathclyde) — VC Fund, 4 deals together
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund, 3 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 3 deals together
- [SIS Ventures](https://shizune.co/investors/profile/sis-ventures) — VC Fund, 3 deals together
- [Calculus Capital](https://shizune.co/investors/profile/calculus-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Norcliffe Capital invest in?

Norcliffe Capital invests primarily in Medical, Biotechnology and Biopharma startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Norcliffe Capital last invest?

The most recent investment recorded for Norcliffe Capital closed in Jun 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co